文献速递血栓与止血

VWF结合适配体隆多拉普肽聚乙二醇增加2B型血管性血友病患者的血小板计数及VWF/FVIII水平

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease.
PubMed 文献 · Blood Adv · 2022-01-01

这项前瞻性2期试验纳入5例2B型血管性血友病患者,皮下给予隆多拉普肽聚乙二醇(BT200)后血小板计数中位数从60升至179×10E9/L(P<.001),VWF抗原从64%升至143%,FVIII活性从67%升至134%,所有血小板减少患者VWF:GPIbM恢复正常、高分子量多聚体出现,停药洗脱期这些改善逆转,证明因果关系。

要点

  • 隆多拉普肽聚乙二醇使2B型VWD患者血小板计数中位数从60升至179×10E9/L(P<.001)。
  • VWF抗原中位数从64%升至143%,FVIII活性从67%升至134%。
  • 所有血小板减少患者VWF:GPIbM恢复正常,VWF瑞斯托霉素辅因子和胶原结合活性升高,高分子量多聚体出现。

核心结论

  • 隆多拉普肽聚乙二醇直接纠正2B型VWD的潜在缺陷,为这类患者提供新的潜在预防和治疗选择。
  • 这些数据为在该类患者中开展2b/3期试验提供基础。

研究设计与样本

  • 前瞻性2期试验,纳入5例2B型VWD患者(男:女=3:2)。
  • 患者在研究第1、4、7天皮下接受3 mg隆多拉普肽聚乙二醇,随后每周6至9 mg直至第28天。
  • 试验在www.clinicaltrials.gov注册,注册号#NCT04677803。

主要发现

  • 血小板计数中位数从60×10E9/L升至179×10E9/L(P<.001)。
  • 循环VWF抗原中位数从64%升至143%,FVIII活性从67%升至134%。
  • 所有血小板减少患者血浆VWF:GPIbM恢复正常,VWF瑞斯托霉素辅因子和VWF胶原结合活性升高,高分子量多聚体出现。
  • 这些改善在药物洗脱期逆转,证明因果关系。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 2B von Willebrand disease (VWD) is characterized by an increased binding affinity of von Willebrand factor (VWF) to platelet glycoprotein Ib. This can lead to clearance of high-molecular-weight (HMW) multimers and thrombocytopenia with a resulting moderate-severe bleeding phenotype. Rondoraptivon pegol (BT200) is a pegylated aptamer binding to the A1 domain of VWF with a novel mechanism of action: it enhances VWF/factor VIII (FVIII) levels by decreasing their clearance. To study the potential benefit of rondoraptivon pegol in patients with type 2B VWD, we conducted a prospective phase 2 trial. Patients with type 2B VWD received 3 mg rondoraptivon pegol subcutaneously on study days 1, 4, and 7, followed by 6 to 9 mg every week until day 28. Five patients (male:female ratio = 3:2) were included. Rondoraptivon pegol rapidly tripled platelet counts from a median of 60 to 179 × 10E9/L (P < .001). Circulating VWF antigen increased from a median of 64% to 143%, which doubled FVIII activity levels from 67% to 134%. In all thrombocytopenic patients, plasma levels of VWF:GPIbM normalized, VWF ristocetin cofactor and VWF collagen-binding activity increased, and HMW multimers appeared. These pronounced improvements reversed during washout of the drug, thus demonstrating causality. The A1 domain binding aptamer directly corrects the underlying defect of type 2B VWD, thus providing a novel potential option for prophylaxis and treatment of patients with this VWD type. These data provide the basis for a phase 2b/3 trial in such patients. This trial was registered at www.clinicaltrials.gov as #NCT04677803.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ay C, Pabinger I, Kovacevic KD, et al. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood Adv. 2022. PMID: 35772170. doi:10.1182/bloodadvances.2022007805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。